SmartZyme BioPharma is a medical technology company based in Jersey City, NJ, developing a next‑generation glucose‑sensing enzyme for use in continuous glucose monitoring devices. The company aims to enable a seamless leap to better performing glucose monitoring for people with diabetes. SmartZyme is accelerating integration of its enzyme into continuous glucose monitoring systems. The article reports the company raised the first tranche of its Series B‑1 funding round, though the amount was not disclosed. WallachBeth Capital acted as the sole placement agent on the transaction. The round was led by OrbiMed Advisors and Virtus Inspire Ventures. SmartZyme uses its proprietary Provolution™ platform to design and engineer proteins and enzymes for therapeutic applications. The company is developing new therapeutics and aims to improve administration of existing biologics. Management says it is preparing to license an innovative enzyme and device for diabetic blood glucose monitoring. SmartZyme is privately held and was founded in November 2013 by Shilo Ben-Zeev and David Baram, Ph.D. The company is based in Ness Ziona, Israel. It recently secured external investment to continue development of its technology and product programs.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2015